Olfr672, encoded by the Or52e15 gene, is a member of the olfactory receptor family in mice. Olfactory receptors are crucial for the sense of smell and belong to the G-protein-coupled receptor (GPCR) family. These receptors, including Olfr672, function by detecting odorant molecules in the nasal epithelium and initiating a series of intracellular responses. These responses typically involve the activation of G proteins, which then influence various downstream effectors such as adenylyl cyclase, leading to changes in intracellular levels of second messengers like cyclic AMP (cAMP). The inhibition of Olfr672, as with many other GPCRs, is not straightforward due to the receptor's complex signaling pathways and lack of well-characterized direct inhibitors. Therefore, potential indirect inhibition strategies target processes and pathways that intersect with GPCR signaling. Beta-adrenergic receptor antagonists such as propranolol, atenolol, and metoprolol can reduce cellular cAMP levels, thereby indirectly affecting GPCR signaling pathways. This reduction in cAMP may impact the function of GPCRs like Olfr672. Calcium channel blockers, including nifedipine and verapamil, modulate intracellular calcium levels, another critical factor in GPCR signaling. Changes in calcium dynamics can indirectly influence the function of GPCRs, including olfactory receptors like Olfr672.
Additionally, targeting other GPCR pathways, such as those mediated by angiotensin II receptors, provides a method to indirectly modulate olfactory receptor function. Antagonists like losartan and candesartan may alter the GPCR signaling landscape, potentially affecting the function of receptors like Olfr672. Alpha-2 adrenergic receptor modulation by agents such as yohimbine and clonidine could also indirectly impact the signaling mechanisms of GPCRs, including olfactory receptors. In summary, the indirect inhibition of Olfr672 involves understanding the broader context of GPCR biology and the interconnected nature of cellular signaling pathways. The chemicals listed provide insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr672. While direct inhibition remains a challenge, these indirect approaches offer potential strategies for modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-adrenergic antagonist, lowers cAMP levels by inhibiting beta-adrenergic receptors. This reduction in cAMP may indirectly affect the signaling pathways of GPCRs like Olfr672. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $77.00 $408.00 | 1 | |
Atenolol, a β1-adrenergic receptor antagonist, decreases cAMP levels by inhibiting β1 receptors. This could indirectly influence GPCR signaling pathways, potentially impacting Olfr672 function. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $105.00 $238.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, may indirectly affect GPCR signaling by altering β1 receptor activity, potentially impacting Olfr672 signaling. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine, a calcium channel blocker, indirectly affects GPCR signaling by modulating intracellular calcium levels, potentially influencing pathways involving Olfr672. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially impacting Olfr672. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Carvedilol, with beta-adrenergic antagonist and alpha-1 blocking activity, can modulate GPCR-mediated signaling, potentially influencing Olfr672. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, impacts GPCR signaling by inhibiting AT1 receptors, which could indirectly affect Olfr672. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $46.00 $92.00 $148.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, may indirectly modulate GPCR signaling pathways, potentially influencing Olfr672. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling and potentially influence Olfr672. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $180.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, potentially impacting Olfr672. | ||||||